Alfacell 2005 Press Releases Press Release Source: Alfacell Corporation Monday January 10, 2005 8:30 am ET Alfacell Corporation to Present at International Pharma & Biotech Licensing Deal-Making Summit BLOOMFIELD, N.J., January 10, 2005 -- Alfacell Corporation (Nasdaq: ACEL) today announced that Andrew P. Aromando, Senior Vice President, Commercial Development and Operations, will present at Strategic Research Institute's (SRI) 10th Anniversary International Pharma & Biotech Licensing Deal-Making Summit, to be held on March 29-31 in Scottsdale, Arizona. The presentation, entitled "Ribonucleases: New Horizons in the Development of Targeted Therapeutics," will begin at 12:00 PM MST (2:00 PM EST) on Thursday, March 31. Alfacell is also a sponsor of the conference. A link to the conference home page on the SRI website will be available on the company's website. About Alfacell Corporation Alfacell Corporation is a global leader and pioneer in the research, development and commercialization of ribonucleases. The Company's mission is to develop new therapeutics based on its ribonuclease technology for the treatment of cancer, infectious diseases and other life-threatening conditions. For more information, please visit www.alfacell.com This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Contact: Alfacell Corporation: Financial Inquiries: Kuslima Shogen, President and CEO RJ Falkner & Company, Inc. Andrew Savadelis, CFO Investor Relations Counsel (973) 748-8082 (800) 377-9893 info@alfacell.com info@rjfalkner.com ------------------------------------------------------------------------ Source: Alfacell Corporation Press Release Source: Alfacell Corporation Tuesday February 8, 2005 Alfacell Corporation Expands ONCONASE® Clinical Program Company Initiates Non-Small Cell Lung Cancer Phase I/II Trial BLOOMFIELD, N.J., February 8,
2005 -- Alfacell Corporation (Nasdaq: ACEL), a leader and pioneer in
the research, development and commercialization of ribonucleases for
the treatment of cancer and other therapeutic applications, today
announced that it has initiated a multi-center, open label, Phase I/II
trial to evaluate ONCONASE® (ranpirnase) in patients with
refractory Non-Small Cell Lung Cancer (NSCLC).
------------------------------------------------------------------------“This new study is designed to assess the therapeutic potential of ONCONASE® in a population that has shown a resistance to other treatments, and to evaluate a new schedule of administration,” stated Kuslima Shogen, Chief Executive Officer of Alfacell Corporation. “The results obtained from Part 1 of this trial will be used to expand our clinical program in the initiation of Phase II trials in esophageal and refractory breast cancers.” According to industry analysts, the market for NSCLC drugs is projected to exceed $4 billion by 2012, in light of the fact that approximately one million new cases of Non-Small Cell Lung Cancer are diagnosed annually. Despite years of research, the prognosis for individuals with lung cancer remains dismal, with a five-year survival rate of less than 15%. Although chemotherapy is the backbone of treatment for metastatic disease, response rates are low, and survival times are poor. Since initial therapy will fail with virtually all individuals with advanced disease, second-line therapy is often necessary. “We believe the expansion of the ONCONASE® clinical program demonstrates our commitment to the building of an oncology franchise across multiple indications, while providing further evidence of Alfacell’s position as a leader in the development of novel therapeutics derived from ribonucleases,” concluded Shogen. Lung cancer is one of the most common cancers in industrialized nations and the leading cause of cancer deaths for both men and women in the United States. In 2004, an estimated 173,700 Americans were diagnosed with lung cancer, and 164,440 of them are expected to die of the disease, which accounts for 25% of all cancer deaths in women and more than 30% of cancer deaths in men. Although lung cancer incidence rates in men have not increased since the mid-1980s, they have continued to rise in women. NSCLC has generated a huge unmet need for more-effective therapies that can prevent disease recurrence and have fewer toxic side effects than current therapies About ONCONASE® ONCONASE®, Alfacell’s lead investigational drug candidate, is currently being evaluated in a confirmatory Phase IIIb study as a treatment for malignant mesothelioma (MM), an asbestos-related cancer. Over 50 sites in the U.S., Canada, Europe, and Australia are participating in the trial. The global MM market is estimated at $300M annually. About NSCLC According to the American Cancer Society, lung cancer is the leading cause of cancer deaths worldwide among men and women. NSCLC is the most common form of lung cancer, accounting for 80 percent of all lung cancer cases. In 2004, NSCLC accounted for approximately 160,000 deaths in the United States. About Alfacell Corporation Alfacell Corporation is a leader in the research and development of ribonucleases for anti-cancer and other therapeutic applications. Alfacell can be found on the World Wide Web at www.alfacell.com. This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.### For further information, please contact Andrew P. Savadelis CFO of Alfacell Corporation, +1-973-748-8082, info@alfacell.com; or financial inquiries, Investor Relations Counsel of RJ Falkner & Company, Inc., +1-800-377-9893,info@rjfalkner.com, for Alfacell Corporation. Press Release Source: Alfacell Corporation Thursday February 24, 2005 8:30 am ET Key ONCONASE(R) Findings Presented at AACR Special Lung Cancer Conference BLOOMFIELD,
N.J., February 24, 2005 – Alfacell Corporation (Nasdaq: ACEL), a
global leader and pioneer in the research, development and
commercialization of ribonucleases for the treatment of cancer and
other therapeutic applications, today announced that the results of a
number of significant experiments are being presented this week at the
American Association for Cancer Research’s Molecular Pathogenesis of
Lung Cancer: Opportunities for Translation to the Clinic conference in
San Diego, California.
“ONCONASE® exhibits tumoricidal effects on cell cultures and animals for the treatment of Non-Small Cell Lung Cancer (NSCLC),” stated Intae Lee, Ph.D., Director of Small Animal Imaging and Animal Model Core, Department of Radiology, University of Pennsylvania. “Our animal studies show that ONCONASE alone effectively kills cancer cells with manageable toxicity. ONCONASE improves radiation response and enhances the efficacy of commonly used chemotherapeutic agents (such as cisplatin and carboplatin) in human NSCLC xenografts of nude mice. We will continue to examine the physiological mechanisms of ONCONASE using a non-invasive imaging method, Magnetic Resonance Imaging (MRI), to strengthen the validity and design of future NSCLC clinical trials.” “These impressive findings further underscore the broad spectrum of ONCONASE activity in cancer indications,” stated Kuslima Shogen, Chief Executive Officer of Alfacell Corporation. “These important pre-clinical findings are being taken into consideration in the development of our NSCLC Clinical Program. According to industry analysts and in light of the fact that approximately one million new cases of NSCLC area diagnosed annually, the market for NSCLC drugs is projected to exceed $4 billion by 2012.” About ONCONASE® ONCONASE®, Alfacell’s lead investigational drug candidate, is currently being evaluated in a confirmatory Phase IIIb study as a treatment for malignant mesothelioma (MM), an asbestos-related cancer. Over 50 sites in the U.S., Canada, Europe, and Australia are participating in the trial. The global MM market is estimated at $300M annually. About NSCLC According to the American Cancer Society, lung cancer is the leading cause of cancer deaths worldwide among men and women. NSCLC is the most common form of lung cancer, accounting for 80 percent of all lung cancer cases. In 2004, NSCLC accounted for approximately 160,000 deaths in the United States. About Alfacell Corporation Alfacell Corporation is a global leader and pioneer in the research, development and commercialization of ribonucleases. Its mission is to develop new therapeutics based on our ribonuclease technology for the treatment of cancer, infectious diseases and other life-threatening conditions. For more information, please visit www.alfacell.com. This press release includes statements that may constitute “forward- looking” statements, usually containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company’s ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company’s periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Contact: Alfacell Corporation: Financial Inquiries: Kuslima Shogen RJ Falkner & Company, Inc. Andrew Savadelis Investor Relations Counsel (973) 748-8082 (800) 377-9893 info@alfacell.com info@rjfalkner.com ------------------------------------------------------------------------ Source: Alfacell Corporation Press Release Source: Alfacell Corporation Friday March 11, 2005 8:30 am ET Alfacell Reports Fiscal Second Quarter 2005 Results and Provides Update on International Patient Accrual
BLOOMFIELD, N.J., March 11,
2005 – Alfacell Corporation (Nasdaq: ACEL) today announced its
financial results for the second quarter of its 2005 fiscal year,
reflecting continued investments in the Company's clinical and
preclinical programs.
Research and development expenses for the second quarter of FY2005 totaled $1.6 million as compared to $.7 million for the second quarter of FY2004. The increase in R&D expenses reflects an expansion in the Company's ONCONASE® Phase IIIb clinical trial for malignant mesothelioma, primarily in Europe, Australia and New Zealand. The Company also incurred higher data management and clinical trial monitoring fees related to the Phase IIIb trial as well as expenses incurred for pharmacology/toxicology and chemistry, manufacturing and controls (CMC) tasks required as part of the NDA process. General and administrative expenses were approximately $.4 million for both the second quarter of FY2005 and FY2004, reflecting higher personnel costs, NASDAQ listing fees and Sarbanes-Oxley compliance fees offset by lower legal and consulting fees. For the three months ended January 31, 2005, the Company reported a net loss attributable to common shareholders of $1.96 million or $.06 per share as compared to a net loss of $1.2 million or $.04 per share for the same period in FY2004. Cash and cash equivalents and short-term investments totaled $7.6 million as of January 31, 2005. ONCONASE® Phase IIIb Trial Update: Accrual of International Patients The Company also reported an extension in the expected time frame for the completion of patient accrual in its malignant mesothelioma Phase IIIb trial. Recent regulatory changes in several large, non-EU countries which have contracted to participate in the trial have occurred. Specifically, local government approvals must now be obtained prior to the initiation of trials in those countries. As a result, patient accrual has been delayed. The Company continues to enroll patients in those countries for which it has government approvals to conduct trials, including the United States, Canada, Poland, Italy, Germany and most recently Australia and New Zealand. The Company has been successful in accelerating patient accrual in these countries and will continue to use its best efforts to accelerate accruals at all sites. The Company expects to achieve projected patient accruals once the local government approvals are granted. The Company continues to focus on rapid patient enrollment in order to accelerate the completion of the Phase IIIb trial in parallel with the completion of all the required sections of the NDA. About Alfacell Corporation Alfacell Corporation is a global leader and pioneer in the research, development and commercialization of ribonucleases. Its mission is to develop new therapeutics based on our ribonuclease technology for the treatment of cancer, infectious diseases and other life-threatening conditions. For more information, please visit www.alfacell.com. This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, difficulties encountered in enrolling patients into its current Phase IIIb clinical trial, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Alfacell Corporation: Financial Inquiries: Kuslima Shogen RJ Falkner & Company, Inc. Andrew Savadelis Investor Relations Counsel (973) 748-8082 (800) 377-9893 info@alfacell.com info@rjfalkner.com ALFACELL CORPORATION (A Development Stage Company) CONDENSED STATEMENTS OF OPERATIONS Three months and six months ended January 31, 2005 and 2004, and the Period from August 24, 1981 (Date of Inception) to January 31, 2005 (Unaudited) Three Months Ended January 31, 2005 2004 Revenue: Sales $ -- $ -- Investment income 33,704 4,530 Other income -- -- Total revenue 33,704 4,530 Costs and expenses: Cost of sales -- -- Research and development 1,554,443 674,089 General and administrative 422,406 420,243 Interest: Related parties, net -- -- Others 12,165 109,786 Total costs and expenses 1,989,014 1,204,118 Loss before state tax benefit (1,955,310) (1,199,588) State tax benefit -- -- Net loss $(1,955,310) $(1,199,588) Loss per basic and diluted common share $ (0.06) $ (0.04) Weighted average number of shares outstanding 35,211,954 28,439,372 August 24, 1981 Six Months Ended (Date of January 31, Inception) to 2005 2004 January 31, 2005 Revenue: Sales $ -- $ -- $ 553,489 Investment income 62,882 8,230 1,491,995 Other income -- -- 90,103 Total revenue 62,882 8,230 2,135,587 Costs and expenses: Cost of sales -- -- 336,495 Research and development 2,475,592 1,311,286 47,430,504 General and administrative 868,003 648,188 24,734,212 Interest: Related parties, net -- -- 1,147,547 Others 43,422 228,401 2,869,665 Total costs and expenses 3,387,017 2,187,875 76,518,423 Loss before state tax benefit (3,324,135) (2,179,645) (74,382,836) State tax benefit 287,975 221,847 2,302,160 Net loss $(3,036,160) $(1,957,798) $(72,080,676) Loss per basic and diluted common share $(0.09) $(0.07) Weighted average number of shares outstanding 34,936,198 27,675,584 See accompanying notes to condensed financial statements. ALFACELL CORPORATION (A Development Stage Company) CONDENSED BALANCE SHEETS January 31, 2005 and July 31, 2004 (Unaudited) January 31, July 31, 2005 2004 (Unaudited) (See Note 1) ASSETS Current assets: Cash and cash equivalents $ 5,630,955 $ 10,147,694 Short-term investments at market which approximates cost 1,978,189 -- Other current assets 228,120 64,771 Total current assets 7,837,264 10,212,465 Property and equipment, net 83,715 56,783 Loan receivable, related party 156,612 151,815 Total assets $ 8,077,591 $ 10,421,063 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Notes payable, net of discount of $4,059 at January 31, 2005 and $34,120 at July 31, 2004 $ 195,941 $ 372,611 Accounts payable 659,748 541,600 Accrued expenses 894,228 625,205 Total liabilities 1,749,917 1,539,416 Stockholders' equity: Preferred stock, $.001 par value; Authorized and unissued, 1,000,000 shares at January 31, 2005 and July 31, 2004 -- -- Common stock, $.001 par value; Authorized 100,000,000 shares at January 31, 2005 and July 31, 2004; Issued and outstanding, 35,245,445 shares at January 31, 2005 and 34,347,885 shares at July 31, 2004 35,245 34,348 Capital in excess of par value 78,373,105 77,891,815 Deficit accumulated during development stage (72,080,676) (69,044,516) Total stockholders' equity 6,327,674 8,881,647 Total liabilities and stockholders' equity $ 8,077,591 $ 10,421,063 See accompanying notes to condensed financial statements. ------------------------------------------------------------------------ Source: Alfacell Corporation Press Release Source: Alfacell Corporation Monday March 28, 2005 8:30 am ET ONCONASE® Granted Orphan Drug Status for Malignant Mesothelioma in Australia BLOOMFIELD, N.J., March
28 — Alfacell Corporation (Nasdaq: ACEL) announced today that the
Therapeutic Goods Administration (TGA) in Australia has granted
ONCONASE® (ranpirnase) Orphan Drug status for the indication of
malignant mesothelioma (MM). ONCONASE is also designated as an Orphan
Drug for MM in Europe.
The TGA defines orphan drug products as "drugs, vaccines or in vivo diagnostic agents which physicians use to treat, prevent or diagnose rare diseases." The TGA's Orphan Drug Program encourages sponsors to market orphan drugs in Australia by reducing costs through waiving fees. In addition, orphan drug status in Australia confers priority evaluation for ONCONASE ahead of other therapies. The Australian Mesothelioma Register, produced by the Epidemiology Unit of the National Occupational Health and Safety Commission (NOHSC), indicates that: * Australia has the world's highest incidence rate of MM * incidence rates of MM have been increasing there since 1965 * there is no indication of when MM incidence rates will start to decline About the ONCONASE Phase IIIb Study ONCONASE, Alfacell's lead investigational drug candidate, is currently being evaluated in a confirmatory Phase IIIb study as a treatment for MM, an asbestos-related cancer. Over 50 sites in the U.S., Canada, Europe, New Zealand and Australia are participating in the trial. The global MM market is estimated at $300M annually. For more information about the trial, please visit http://www.centerwatch.com/alfacellmeso . About Alfacell Corporation Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of ribonucleases (RNases). The Company's mission is to develop new therapeutics based on its proprietary RNase technology for the treatment of cancer, infectious diseases and other life-threatening conditions. For more information, please visit http://www.alfacell.com . This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, difficulties encountered in enrolling patients into its current Phase IIIb clinical trial, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward- looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. ------------------------------------------------------------------------ Source: Alfacell Corporation Press Release Source: Alfacell Corporation Wednesday April 20, 2005 3:16 pm ET New ONCONASE® Data on Non-Small Cell Lung Cancer Presented at AACR Annual Meeting BLOOMFIELD, N.J., April 20,
2005 – Alfacell Corporation (Nasdaq: ACEL), a biopharmaceutical company
focused on the discovery, development and commercialization of novel
therapeutics for cancer and other life-threatening diseases, today
announced that Intae Lee, Ph.D., Department of Radiology, University of
Pennsylvania, presented new data yesterday at the American Association
for Cancer Research (AACR) annual meeting in Anaheim, California. These
studies supported earlier research showing ONCONASE® (ranpirnase),
Alfacell's lead investigational drug candidate, to be a novel and
promising treatment for Non-Small Cell Lung Cancer (NSCLC). Dr. Lee
presented the following abstract: "Physiological Mechanisms of the
Enhanced Cytotoxicity of Cisplatin and Carboplatin in A549 Human Lung
Tumors by the RNase ONCONASE."
ADVERTISEMENT"Our current studies again showed the effectiveness of the cytotoxic RNase, ONCONASE, against NSCLC," stated Dr. Lee. "When ONCONASE was combined with either cisplatin or carboplatin, the chemo-sensitivity was significantly enhanced with manageable toxicity. Furthermore, in large-size tumors -- including those unsuccessfully treated with either cisplatin or carboplatin -- ONCONASE effectively showed inhibition of tumor growth, while a second treatment of cisplatin and carboplatin did not." Dr. Lee concluded, "Thus, ONCONASE shows promise as a therapeutic alternative for commonly used chemotherapeutic agents (such as cisplatin and carboplatin) for the treatment of human NSCLC. This data also supports the prospects for Alfacell's current NSCLC trial." In February 2005, the Company initiated a multicenter, open-label, Phase I/II trial in the United States evaluating ONCONASE in patients with refractory NSCLC. "We are pleased with the growing compendium of data supporting ONCONASE as a potent, efficacious cytotoxic agent -- even in large, resistant tumor types," stated Kuslima Shogen, Chief Executive Officer of Alfacell Corporation. "These new findings again illustrate that ONCONASE represents a truly novel and promising approach to the treatment of NSCLC, where such therapies are needed." About NSCLC According to the American Cancer Society, lung cancer is the leading cause of cancer deaths worldwide among men and women. NSCLC is the most common form of lung cancer, accounting for 80 percent of all lung cancer cases. In 2004, NSCLC accounted for approximately 160,000 deaths in the United States. According to industry analysts, the NSCLC drug market is projected to exceed $4 billion by 2012. About Alfacell Corporation Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer and other life-threatening diseases, using its proprietary ribonuclease (RNase) technology platform. For more information, please visit www.alfacell.com. This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. ------------------------------------------------------------------------ Source: Alfacell Corporation Press Release Source: Alfacell Corporation Tuesday April 26, 2005 8:30 am ET Alfacell Corporation Retains New Investor Relations Firm BLOOMFIELD, N.J., April 26, 2005 -- Alfacell Corporation (Nasdaq: ACEL), a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer and other life-threatening diseases, today announced the selection of Elite Financial Communications Group as the Company's new investor relations firm. Alfacell and Elite will work closely to further develop the Company's corporate communications strategy, and to help create customized, high-impact programs and messages that accentuate the Company's vision and expertise. This fully integrated suite of services will focus on increasing awareness of the Company's growth strategies among individual investors, investment professionals, industry analysts and the media. "These are truly exciting times at Alfacell," stated Kuslima Shogen, Chief Executive Officer of Alfacell Corporation. "As a result, we needed an experienced, results-oriented investor relations team to help us raise our profile within the investment community, and to reach a broader audience through the media. We explored many options, and Elite emerged as the clear choice." Dodi Handy, President and CEO of Elite, added, "With its groundbreaking science, novel product pipeline and sound business strategy, Alfacell is well-positioned for success. We look forward to playing a meaningful role in ensuring that the Wall Street community recognizes and rewards Alfacell as the compelling market opportunity the Company so clearly represents." About Alfacell Corporation Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer and other life-threatening diseases, using its proprietary ribonuclease (RNase) technology platform. ONCONASE® (ranpirnase), Alfacell's lead investigational drug candidate, is currently being evaluated in a confirmatory Phase IIIb trial for malignant mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC). According to industry data, the estimated global market for MM is $300 million, while the NSCLC market is expected to exceed $4 billion by 2012. For more information, please visit www.alfacell.com. About Elite Financial Communications Group, LLC Headquartered in Lake Mary, Florida, Elite Financial Communications Group combines diverse expertise, influence, talent and capabilities to achieve quantifiable results for both publicly traded and privately held companies. Established in December 2001 by a partnership group composed of highly reputable financial, marketing and business experts, Elite is rapidly earning international distinction for challenging industry convention and for taking the lead in establishing best practices for proactive financial communications, investor relations and strategic resourcing. For more information on Elite, please visit www.efcg.net. This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, difficulties encountered in enrolling patients, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Contact: Alfacell Corporation: Investor/Media Relations: Kuslima Shogen Elite Financial Communications Andrew Savadelis Andrea Strittmatter (973) 748-8082 (407) 585-1080 info@alfacell.com acel@efcg.net Press Release Source: Alfacell Corporation Wednesday May 25, 2005 8:30 am ET Alfacell Corporation Announces Appointment of Robert D. Love as New Chief Financial Officer Former SmithKline Beecham Executive Joins the Alfacell Management Team BLOOMFIELD, N.J., May 25, 2005 -- Alfacell Corporation (Nasdaq: ACEL), a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer and other life-threatening diseases, today announced the appointment of Robert D. Love, CPA, MBA, to the position of Chief Financial Officer, effective immediately. Love succeeds Andrew Savadelis, who is leaving the company to pursue other business opportunities. "We thank Andrew Savadelis for his contributions, and wish him well in his new endeavors," stated Kuslima Shogen, Chief Executive Officer of Alfacell. "We are also very pleased to welcome Bob Love to our management team. Bob is a highly accomplished, senior-level executive in the pharmaceutical industry. His proven track record and extensive experience in high-profile leadership positions across several disciplines will prove invaluable to our continuing efforts to expand and execute our business strategy." Mr. Love has over 25 years of domestic and international experience in the pharmaceutical industry. Love has held senior-level positions in Finance, Corporate Development and Marketing with P&L responsibility at large, privately-held companies as well as major, publicly-traded global pharmaceutical corporations. Most recently, Love served as Senior Vice President, CFO and COO of TriGenesis Therapeutics, Inc., a start-up specialty pharmaceutical company that he co-founded. From 1998 through 2002, Love served as both Senior Vice President in charge of Business Partnering and Senior Vice President, Finance and Acquisitions at Innovex, a division of Quintiles Transnational Corporation, the world's leading pharmaceutical services organization. Prior to Innovex, Love was CFO at Mutual Pharmaceuticals/United Research Labs from 1995 to 1998. From 1976 through 1995, Love held several senior management positions at SmithKline Beecham, including Vice President and Director, Strategic Product Development -- Worldwide from 1993 to 1995, Vice President, CFO in the UK -- one of the Company's largest ex-U.S. operations -- from 1991 to 1993, and Director, Finance -- North America from 1988 to 1991. Mr. Love began his career as an accountant at Coopers and Lybrand in 1972. He earned a B.A. in Accounting from Rutgers University and a MBA with a concentration in Finance/Marketing from Villanova University. He is a Certified Public Accountant. "I am very pleased to be joining the Alfacell team at such an exciting time in the Company's history," stated Love. "Alfacell has a sound corporate vision, talented leadership group, novel technology platform and promising portfolio of product candidates. As such, the Company is very well-positioned to achieve several important milestones, and is on a clear path toward becoming a fully integrated biopharmaceutical company. I look forward to working with my new colleagues to accelerate our growth in the near-term and the future." About Alfacell Corporation Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer and other life-threatening diseases, using its proprietary ribonuclease (RNase) technology platform. ONCONASE® (ranpirnase), Alfacell's lead investigational drug candidate, is currently being evaluated in a confirmatory Phase IIIb trial for malignant mesothelioma (MM) and a Phase I/II trial in Non-Small Cell Lung Cancer (NSCLC). According to industry data, the estimated global market for MM is $300 million, while the NSCLC market is expected to exceed $4 billion by 2012. For more information, please visit www.alfacell.com. This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the enrollment of patients, the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Alfacell Corporation: Investor/Media Relations: Kuslima Shogen Elite Financial Communications Robert Love Andrea Strittmatter (973) 748-8082 (407) 585-1080 info@alfacell.com acel@efcg.net ------------------------------------------------------------------------ Source: Alfacell Corporation Press Release Source: Alfacell Corporation Wednesday June 8, 2005 8:30 am ET Alfacell Corporation to Present at Informed Investors Biotechnology / Pharmaceuticals / Healthcare Forum BLOOMFIELD, N.J., June 8, 2005 – Alfacell Corporation (Nasdaq: ACEL), a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer and other life-threatening diseases, today announced that Andrew Aromando, Senior Vice President, Commercial Development and Operations, is scheduled to present at the Informed Investors Biotechnology/Pharmaceuticals/Healthcare Forum on Wednesday, June 15 at The Princeton Club of New York. Alfacell is one of 20 invited companies with senior executives presenting at the Forum. Other companies scheduled to present include Crucell N.V. and Sanofi-Aventis. For more information, please visit the Forum webpage at www.informedinvestors.com. About Alfacell Corporation Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer and other life-threatening diseases, using its proprietary ribonuclease (RNase) technology platform. ONCONASE® (ranpirnase), Alfacell's lead investigational drug candidate, is currently being evaluated in a confirmatory Phase IIIb trial for malignant mesothelioma (MM) and a Phase I/II trial in Non-Small Cell Lung Cancer (NSCLC). According to industry data, the estimated global market for MM is $300 million, while the NSCLC market is expected to exceed $4 billion by 2012. For more information, please visit www.alfacell.com. This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the enrollment of patients, the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. CONTACT: Alfacell Corporation: Investor/Media Relations: Kuslima Shogen Elite Financial Communications Robert Love Andrea Strittmatter (973) 748-8082 (407) 585-1080 info@alfacell.com acel@efcg.net ------------------------------------------------------------------------ Source: Alfacell Corporation Press Release Source: Alfacell Corporation Thursday June 9, 2005 8:30 am ET Dr. Jacob V. Maizel, Jr. and Dr. Susanna Rybak Join Alfacell's Scientific Advisory Board BLOOMFIELD, N.J., June 9,
2005 – Alfacell Corporation (Nasdaq: ACEL - News) today announced
the appointment of Dr. Jacob V. Maizel, Jr. and Dr. Susanna Rybak from
the National Institutes of Health (NIH) to the Company's Scientific
Advisory Board (SAB). Drs. Maizel and Rybak will work closely with Dr.
David Sidransky, Chairman of the Company's Scientific Advisory Board,
as well as the other members to optimize the potential of the Company's
proprietary ribonuclease (RNase) technology.
"I have long admired both Drs. Maizel and Rybak. Our long term collaboration with Dr. Rybak during her tenure at the National Cancer Institute (NCI) has been extremely valuable," stated Kuslima Shogen, Chief Executive Officer of Alfacell. "Each brings an extraordinarily high level of influence and experience in their respective fields. Their contributions will prove to be of tremendous value to Alfacell, as we continue to accelerate our research and drug development efforts." Dr. Maizel stated, "After a career in basic research on protein and RNA structure, I am enthusiastically looking forward to being involved with applications of drugs that target RNA." Dr. Rybak added, "Much of my career has involved developing the rationale for RNase-based therapeutics. I am very excited about the possibilities involved in bringing this to fruition." About Jacob V. Maizel, Jr., Ph.D. With a distinguished career spanning nearly 40 years, Dr. Maizel has won international recognition for his many achievements in the fields of mammalian virology, cell and computational biology. From 1983 to 2005, Dr. Maizel was Chief of the Laboratory of Experimental and Computational Biology at the NCI. Upon his appointment to the NCI, he led the creation of a supercomputing facility known today as the Advanced Biomedical Computing Center (ABCC). This is the only supercomputing system entirely dedicated to biomedical research and available to NCI, NIH and extramural scientists. For his work in developing graphical methods for understanding structure, organization and evolution of genes, Dr. Maizel was awarded the U.S. Public Health Service Superior Award in 1982. His efforts in fostering high performance computing in biomedical research were recognized when he received an NIH Merit Award in 1993. Dr. Maizel is a featured speaker at industry seminars and serves on the editorial boards of a number of medical journals. He has previously served as a professor in the Department of Cell Biology of the Albert Einstein College of Medicine, and on the High Performance Computing, Communication and Information Technology committee that manages a billion dollar program across more than a dozen agencies. After receiving a Doctorate in Biochemistry from the California Institute of Technology in 1959, he initiated research on the structure and replication of poliovirus while in the Laboratory of Cell Biology at the NIH. This research led to his discovery of a method to accurately analyze human virus and cellular proteins, which ultimately revolutionized the study of proteins and served as a catalyst for many important medical breakthroughs in a wide range of fields. About Susanna Rybak, Ph.D. For over 25 years, Dr. Rybak's research has centered on the biology of RNases, antibody engineering and drug targeting. Her laboratory at the NCI developed the groundwork for RNase-based therapeutics for non-Hodgkin's lymphoma (NHL) and breast cancer. She has been a long-term collaborator with Alfacell in the development of RN-321, a novel conjugate (ranpirnase and an anti-CD22 antibody) for the treatment of NHL. This compound is being developed by Alfacell and the NCI under a Collaborative Research and Development Agreement (CRADA). After earning a Ph.D. from the University of California-San Francisco, where she studied hormone mechanism of action, and subsequent to post-doctoral training at Stanford University and the Weizmann Institute of Science in Israel, Dr. Rybak was appointed an Assistant Professor of Pathology at Harvard Medical School and Research Associate in Pathology at Brigham and Women's Hospital in Boston. While at Harvard, Dr. Rybak's research determined that RNases could potentially be engineered into therapeutic agents by way of chemical and/or genetic means. After joining the NIH in 1989, she confirmed this hypothesis with a variety of RNases, both human and amphibian. Dr. Rybak's achievements have been honored with a number of awards, including the Japanese Society for the Promotion of Science Award and the Merit Award from the NCI. Dr. Rybak has been widely published in peer-reviewed journals, and frequently serves on review committees and speaks at national and international biotechnology conferences. She has also held numerous visiting appointments in universities and industry, including the University of Washington and Biogen, respectively. About Alfacell Corporation Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer and other life-threatening diseases, using its proprietary ribonuclease (RNase) technology platform. ONCONASE® (ranpirnase), Alfacell's lead investigational drug candidate, is currently being evaluated in a confirmatory Phase IIIb trial for malignant mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC). According to industry data, the estimated global market for MM is $300 million, while the NSCLC market is expected to exceed $4 billion by 2012. For more information, please visit www.alfacell.com. This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Alfacell Corporation: Investor/Media Relations: Kuslima Shogen Elite Financial Communications Robert Love Andrea Strittmatter (973) 748-8082 (407) 585-1080 info@alfacell.com acel@efcg.net ------------------------------------------------------------------------ Source: Alfacell Corporation Press Release Source: Alfacell Corporation Monday June 20, 2005 9:04 am ET Alfacell CEO Kuslima Shogen Addresses 7th International Meeting on Ribonucleases BLOOMFIELD, N.J., June 20, 2005
-- Alfacell Corporation (Nasdaq: ACEL), a biopharmaceutical company
focused on the discovery, development and commercialization of novel
therapeutics for cancer and other life-threatening diseases, today
announced that Kuslima Shogen, Chairman and Chief Executive Officer,
addressed the closing session of the 7th International Meeting on
Ribonucleases (IMR) in Stara Lesna, Slovak Republic yesterday evening.
Alfacell was a sponsor of the Meeting.
Please visit the IMR website at http://imb.savba.sk/imr2005/ for more information. About Alfacell Corporation Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer and other life-threatening diseases, using its proprietary ribonuclease (RNase) technology platform. ONCONASE® (ranpirnase), Alfacell's lead investigational drug candidate, is currently being evaluated in a confirmatory Phase IIIb trial for malignant mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC). According to industry data, the estimated global market for MM is $300 million, while the NSCLC market is expected to exceed $4 billion by 2012. For more information, please visit www.alfacell.com. This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the enrollment of patients, the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third- party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Alfacell Corporation: Investor/Media Relations: Kuslima Shogen Elite Financial Communications Robert Love Stephanie Noiseux (973) 748-8082 (407) 585-1080 info@alfacell.com acel@efcg.net ------------------------------------------------------------------------ Source: Alfacell Corporation Press Release Source: Alfacell Corporation Tuesday July 5, 2005 8:00 am ET Alfacell Corporation to Participate in 7th Annual Anti-Cancer Drug Discovery and Development Conference BLOOMFIELD, N.J., July 5, 2005
– Alfacell Corporation (Nasdaq: ACEL), a biopharmaceutical company
focused on the discovery, development and commercialization of novel
therapeutics for cancer and other life-threatening diseases, today
announced that Andrew Aromando, Senior Vice President, Commercial
Development and Operations, is a scheduled panelist at Strategic
Research Institute's (SRI) 7th Annual Anti-Cancer Drug Discovery and
Development Conference July 12-13, 2005 at the Sheraton Boston Hotel in
Boston, Massachusetts. Mr. Aromando will participate in the "Valuation
-- Science or Art?" session, which will focus on techniques that help
determine the value of products, technologies and companies as well as
appropriate terms for partnering and licensing deals.
Alfacell is one of over 40 companies with senior executives invited to speak at the conference. Other companies with participants include Amgen, Bristol-Myers Squibb, Genzyme, Johnson and Johnson, Merck, Novartis and Pfizer. For more information, please visit the conference website at www.srinstitute.com/cs344. About Alfacell Corporation Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer and other life-threatening diseases, using its proprietary ribonuclease (RNase) technology platform. ONCONASE® (ranpirnase), Alfacell's lead investigational drug candidate, is currently being evaluated in a confirmatory Phase IIIb trial for malignant mesothelioma (MM) and a Phase I/II trial in Non-Small Cell Lung Cancer (NSCLC). According to industry data, the estimated global market for MM is $300 million, while the NSCLC market is expected to exceed $4 billion by 2012. For more information, please visit www.alfacell.com. This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the enrollment of patients, the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Contact: Alfacell Corporation: Investor/Media Relations: Kuslima Shogen Elite Financial Communications Robert Love Stephanie Noiseux (973) 748-8082 (407) 585-1080 info@alfacell.com acel@efcg.net ------------------------------------------------------------------------ Source: Alfacell Corporation Press Release Source: Alfacell Corporation Thursday July 21, 2005 9:10 am ET Alfacell Corporation to Explore Uses for New Ribonuclease Drug Candidate AC 03-636 to Be Evaluated for Activity Against Dengue Virus by the Novartis Institute for Tropical Diseases BLOOMFIELD, N.J., July 21
– Alfacell Corporation (Nasdaq: ACEL) today announced the signing of a
Material Transfer Agreement (MTA) with The Novartis Institute for
Tropical Diseases (NITD), based in Singapore, for the Company's novel
ribonuclease (RNase) anti-viral drug candidate, AC 03-636. Under the
terms of the agreement, NITD receives rights from Alfacell to conduct
in vitro tests using cell-based assays to evaluate the activity of AC
03-636 in Dengue fever, with in vivo studies in animal models
potentially to follow. Alfacell will also provide technical assistance
for all studies to be conducted by NITD. No additional details were
disclosed.
Andrew Aromando, Senior Vice President, Commercial Development and Operations at Alfacell, stated, "NITD is a global center of excellence in the area of Dengue fever research, possessing exceptional scientific resources and capabilities. Their commitment to reducing the incidence of deadly infectious diseases that affect millions in developing countries is unmatched. As such, NITD is extremely well-suited to conduct further research on AC 03-636." About Alfacell Corporation Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer and other life-threatening diseases, using its proprietary ribonuclease (RNase) technology platform. ONCONASE® (ranpirnase), Alfacell's lead investigational drug candidate, is currently being evaluated in several studies, including a confirmatory Phase IIIb trial for malignant mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC). According to industry data, the estimated global market for MM is $300 million, while the NSCLC market is expected to exceed $4 billion by 2012. For more information, please visit www.alfacell.com. About Dengue Fever Dengue fever is a mosquito-borne viral infection, causing fever and severe joint pain, hemorrhage and shock in some cases and, in the most severe cases, death. It is found in tropical and sub-tropical regions across five continents. The World Health Organization estimates that 50 million cases occur each year, requiring 500,000 hospitalizations. The global prevalence of Dengue fever has risen dramatically, and the disease is now endemic in more than 100 countries in Africa, the Americas, and the Eastern Mediterranean, with the most serious outbreaks found in Southeast Asia and the Western Pacific. Presently, there is no known cure or vaccine for Dengue fever. This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the enrollment of patients, the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Alfacell Corporation: Investor/Media Relations: Kuslima Shogen Elite Financial Communications Robert Love Stephanie Noiseux (973) 748-8082 (407) 585-1080 info@alfacell.com acel@efcg.net Press Release Source: Alfacell Corporation Tuesday August 30, 2005 8:30 am ET Alfacell Provides Update on ONCONASE® Malignant Mesothelioma Phase IIIb Trial BLOOMFIELD, N.J., August 30,
2005 – Alfacell Corporation (Nasdaq: ACEL) today provided an update on
the status of its international, confirmatory Phase IIIb malignant
mesothelioma trial for ONCONASE® (ranpirnase), the Company's lead
investigational drug candidate:
* Nearly 90% of the patients required per the study design for full patient accrual are now enrolled. * Active patient enrollment is ongoing at leading cancer centers in the United States, Canada, Germany, Italy, Poland, Australia and New Zealand. * Earlier this year, the Company reported that recent regulatory changes in several large, non-EU countries had delayed the opening of new sites for the study. The Company is now pleased to announce that government approvals have been obtained and sites recently opened in Russia, Romania, Mexico and Brazil. "This progress illustrates our strong focus on accelerating the completion of the ONCONASE malignant mesothelioma clinical program," stated Kuslima Shogen, Chief Executive Officer of Alfacell. "Our extensive, global patient recruitment efforts continue to move us closer to achieving important milestones, such as completing patient enrollment for the Phase IIIb study and the non-clinical sections of the rolling NDA." The Company will continue to provide updates on the trial as key developments occur. About Alfacell Corporation Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer and other life-threatening diseases, using its proprietary ribonuclease (RNase) technology platform. ONCONASE® (ranpirnase), Alfacell's lead investigational drug candidate, is currently being evaluated in several studies, including a Phase IIIb trial for malignant mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC). According to industry data, the estimated global market for MM is $300 million, while the NSCLC market is expected to exceed $4 billion by 2012. For more information,please visit www.alfacell.com. About the ONCONASE Phase IIIb Study ONCONASE, Alfacell's lead investigational drug candidate, is currently being evaluated in a centrally randomized, open label, confirmatory Phase IIIb trial as a treatment for malignant mesothelioma (MM), an asbestos-related cancer that afflicts approximately 4,000 people in the U.S. each year. Over 40 U.S. and international sites are participating in the study. For more information, please visit www.centerwatch.com/alfacellmeso. This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe", "estimate", "project", "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the enrollment of patients, the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward- looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Contact: Alfacell Corporation: Kuslima Shogen Robert Love (973) 748-8082 info@alfacell.com Investor/Media Relations Elite Financial Communications Stephanie Noiseux (407) 585-1080 acel@efcg.net Press Release Source: Alfacell Corporation Tuesday September 6, 2005 8:30 am ET New ONCONASE® Non-Small Cell Lung Cancer Data Presented at ISOTT Annual Meeting BLOOMFIELD, N.J., September 6,
2005 – Alfacell Corporation (Nasdaq: ACEL) a biopharmaceutical company
focused on the discovery, development and commercialization of
ribonuclease (RNase) therapeutics for cancer, today announced that
Intae Lee, Ph.D., Department of Radiology, University of Pennsylvania,
presented new data on the effectiveness of ONCONASE against non-small
cell lung cancer (NSCLC) at the 33rd Annual Meeting of the International Society on Oxygen Transport to Tissue
(ISOTT) held from August 28 through September 1 in Brisbane, Australia.
Dr. Lee's presentation was entitled, 'Possible Mechanisms of Improved
Radiation Response by the Cytotoxic RNase, ONCONASE®, on A549 Human
Lung Cancer Xenografts of Nude Mice.'
"Our current studies illustrate the remarkable effect of ONCONASE as a single agent against NSCLC," stated Dr. Lee. "Specifically, ONCONASE, when combined with radiation therapy, was shown to enhance the radiation- sensitivity to treatment in tumor cells without causing the common radiation-induced tissue damage to non-tumor cells." Dr. Lee concluded, "ONCONASE likely enhanced the radiation response of A549 human NSCLC in vitro and in vivo due to its combined mechanisms of reduced O2 consumption rate, inhibition of sub-lethal damage repair, induced apoptosis, and temporarily improved tumor blood flow." "These studies offer further validation of ONCONASE's unique molecular mechanisms and potential as a novel and promising treatment for NSCLC," stated Kuslima Shogen, Chief Executive Officer of Alfacell. "We also believe that the current suite of data supporting ONCONASE as a potent, efficacious cytotoxic agent against non-small cell lung carcinoma and other solid tumors will continue to expand." About Alfacell Corporation Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer, using its proprietary ribonuclease (RNase) technology platform. ONCONASE® (ranpirnase), Alfacell's lead investigational drug candidate, is currently being evaluated in several studies, including a Phase IIIb trial for malignant mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC). For more information, please visit http://www.alfacell.com . About Non-Small Cell Lung Cancer (NSCLC) According to the American Cancer Society, lung cancer is the leading cause of cancer deaths worldwide among men and women. NSCLC is the most common form of lung cancer, accounting for 80 percent of all lung cancer cases. In 2004, NSCLC accounted for approximately 160,000 deaths in the United States. According to industry analysts, the NSCLC drug market is projected to exceed $4 billion by 2012. This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Contact: Alfacell Corporation: Investor/Media Relations: Kuslima Shogen Elite Financial Communications Robert Love Stephanie Noiseux (973) 748-8082 (407) 585-1080 info@alfacell.com acel@efcg.net Press Release Source: Alfacell Corporation Monday September 26, 2005 9:00 am ET New Publication in Leading Cancer Journal Highlights Effectiveness of ONCONASE as Novel Anti-Cancer Agent BLOOMFIELD, N.J., September 26,
2005 – Alfacell Corporation (Nasdaq: ACEL) today announced that a
new publication reviewing ONCONASE® (ranpirnase), the Company's
lead investigational drug candidate, appears in the current edition of
the journal Cancer Investigation.
The publication, entitled, "Ribonucleases as a Novel Pro-Apoptotic Anticancer Strategy: Review of the Preclinical and Clinical Data for Ranpirnase," describes ONCONASE as representing a "novel approach to mechanism-based cancer therapy," and states that the results of multiple tumor-specific trials have been interpreted as showing "clinical effectiveness in mesothelioma, breast cancer and non-small cell lung cancer." The publication also affirms that the Company's proprietary RNases have "much potential as chemotherapeutics." The authors of the publication are John Costanzi, M.D., Lone Star Oncology, Austin, Texas, David Sidransky, M.D., Johns Hopkins University Medical Center, Baltimore, Maryland; Ami Navon, Ph.D., Weizmann Institute of Science, Rehovot, Israel, and Howard Goldsweig, M.D., ClinPro Oncology, Bound Brook, New Jersey. According to the authors, "Efforts to improve cancer therapy have focused on the development of more selective, biological mechanism-based agents that can overcome tumor resistance and minimize toxic effects to normal cells. Cytotoxic RNases represent one such mechanism-based approach. These relatively small proteins selectively attack malignant cells, triggering apoptotic response and inhibiting protein synthesis. As such, RNases represent a new therapeutic class with broad clinical applications and new biologic activities." ONCONASE, currently being evaluated in a Phase IIIb confirmatory trial in malignant mesothelioma and a Phase I / II trial in non-small cell lung cancer (NSCLC), is the first RNase to reach late-stage clinical development. "This publication effectively underscores the potential of ONCONASE as a novel and promising anti-cancer agent," stated Kuslima Shogen, Chief Executive Officer of Alfacell. "As we approach full enrollment of the pivotal ONCONASE malignant mesothelioma trial, advance the current ONCONASE NSCLC trial and continue efforts to move our promising early-stage candidates into the clinic, we intend to build on the already significant suite of data validating the therapeutic potential of Alfacell's unique RNase technology platform." About Alfacell Corporation Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer, using its proprietary ribonuclease (RNase) technology platform. ONCONASE® (ranpirnase), Alfacell's lead investigational drug candidate, has been successfully administered to over 850 patients with a variety of solid tumors, and is currently being evaluated in a Phase IIIb trial for malignant mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC). For more information, please visit www.alfacell.com. This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Contact: Alfacell Corporation: Investor/Media Relations: Kuslima Shogen Elite Financial Communications Robert Love Stephanie Noiseux (973) 748-8082 (407) 585-1080 info@alfacell.com acel@efcg.net Press Release Source: Alfacell Corporation Tuesday September 27, 2005 9:00 am ET Alfacell CEO Tina Shogen Named to First Annual PharmaVOICE 100 List of Most Inspiring People BLOOMFIELD, N.J., September 27,
2005 – Alfacell Corporation (Nasdaq: ACEL) today announced that Kuslima
("Tina") Shogen, Chairman and Chief Executive Officer, was selected as
one of the healthcare industry's 100 Most Inspiring People in a special
issue of PharmaVOICE, a leading monthly trade publication.
The PharmaVOICE 100 "represents a broad cross-section of industry sectors - pharmaceutical, biotechnology, contract research, clinical trials, research and development, patient education, patient recruitment, advertising, technology, and many others," according to the publication. Recipients profiled for the PharmaVOICE 100 were described as having a "passion for the industry, the work they do, their colleagues, and most importantly, the people who are impacted by what they bring to the table. Their focus is clear: improving the discovery, development, access, and understanding of life-improving and life-saving medications. Their passion is felt by all those whose lives they touch. They've made a concerted effort to put a more human face on the lifesciences industry. They have a personal management style that stresses integrity, decency, and character." Shogen was one of 27 individuals profiled in the 'Commanders and Chiefs' section of the list, inclusive of "top-level executives at the forefront, leading change within the industry and guiding their companies to success." "I am truly honored to have been named to the PharmaVOICE 100," stated Shogen. "To be acknowledged by my peers as worthy of such a prestigious honor is humbling." Shogen concluded, "Being a part of this industry is a reward unto itself. There are few other endeavors in life more satisfying than advancing science for the greater good. I, along with my dedicated colleagues, look forward to continuing to develop Alfacell's technology into new and better medicines with passion and purpose." For more information about the PharmaVOICE 100, visit www.pharmavoice.com. About Alfacell Corporation Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer, using its proprietary ribonuclease (RNase) technology platform. ONCONASE® (ranpirnase), Alfacell's lead investigational drug candidate, has been successfully administered to over 850 patients with a variety of solid tumors, and is currently being evaluated in a Phase IIIb trial for malignant mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC). For more information, please visit www.alfacell.com. This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Contact: Alfacell Corporation: Investor/Media Relations: Kuslima Shogen Elite Financial Communications Robert Love Stephanie Noiseux (973) 748-8082 (407) 585-1080 info@alfacell.com acel@efcg.net Press Release Source: Alfacell Corporation Tuesday October 4, 2005 8:30 am ET Alfacell to Present at Second International Symposium on Malignant Mesothelioma BLOOMFIELD, N.J., October 4, 2005 – Alfacell Corporation (Nasdaq: ACEL) today announced that the Company will present at the Second International Symposium on Malignant Mesothelioma, to be held in Las Vegas from October 6-8, 2005.
The presentation, entitled, "Two ONCONASE® Clinical Trials in MM Patients Evaluated Using the EORTC Prognostic Model," will analyze whether there is a difference in survival between ONCONASE study patients categorized as 'Good' or 'Poor' risk for survival, using European Organization for the Research and Treatment of Cancer (EORTC) prognostic scores. The EORTC model was recently validated in a study from St. Bartholomew's Hospital (Lung Cancer and Mesothelioma Unit, Medical Oncology) and The London Lung Cancer Group -- both based in London, UK -- published in the Journal of Clinical Oncology (Volume 23:1, January 1, 2005). Alfacell, along with companies such as Eli Lilly, Merck and Fujirebio Diagnostics, has provided an educational grant in support of the symposium, which is organized by the Mesothelioma Applied Research Foundation (MARF), a national nonprofit organization dedicated to eradicating mesothelioma as a life-threatening disease. For more information on the symposium or MARF,visit www.marf.org. About Alfacell Corporation Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer, using its proprietary ribonuclease (RNase) technology platform. ONCONASE® (ranpirnase), Alfacell's lead investigational drug candidate, has been successfully administered to over 850 patients with a variety of solid tumors, and is currently being evaluated in a Phase IIIb trial for malignant mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC). For more information, please visit www.alfacell.com. This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Contact: Alfacell Corporation: Investor/Media Relations: Kuslima Shogen Elite Financial Communications Robert Love Dodi Handy (973) 748-8082 (407) 585-1080 info@alfacell.com acel@efcg.net Press Release Source: Alfacell Corporation Tuesday October 11, 2005 9:57 am ET Alfacell Receives First-Ever Pioneer Award for Mesothelioma Research From Mesothelioma Applied Research Foundation BLOOMFIELD, N.J., October 11,
2005 – Alfacell Corporation (Nasdaq: ACEL) today announced that the
Company was presented with a "Pioneer Award" from the Mesothelioma
Applied Research Foundation (MARF) at its Second International Symposium on Malignant Mesothelioma,
held last week in Las Vegas. The Pioneer Award was introduced by MARF
this year to honor companies that have made substantial contributions
to the field of mesothelioma research.
"It is a great honor to receive one of the first MARF Pioneer Awards," stated Kuslima Shogen, Chief Executive Officer of Alfacell, who accepted the award on behalf of the Company. "Even greater was the opportunity to meet many patients and others who have lost loved ones to mesothelioma. It was humbling to receive their praise, and inspiring to witness their grace and determination to conquer this terrible disease." Shogen concluded, "MARF has done exceptional work in drawing much-needed attention to malignant mesothelioma, an insidious cancer that affects thousands around the world. Through the annual symposium, MARF also provides a unique, interdisciplinary forum for discussion of the scientific and clinical advances in the treatment of this disease. We salute MARF for their efforts, and will continue to work with them on the mission to find a cure." In addition to Alfacell, other inaugural Pioneer Award recipients included Eli Lilly, Merck, Biogen Idec and Fujirebio Diagnostics. For more information about MARF, a national nonprofit organization dedicated to eradicating mesothelioma as a life-threatening disease, visit www.marf.org. About Alfacell Corporation Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer, using its proprietary ribonuclease (RNase) technology platform. ONCONASE® (ranpirnase), Alfacell's lead investigational drug candidate, has been successfully administered to over 850 patients with a variety of solid tumors, and is currently being evaluated in a Phase IIIb trial for malignant mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC). For more information, please visit www.alfacell.com. This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Contact: Alfacell Corporation: Investor/Media Relations: Kuslima Shogen Elite Financial Communications Robert Love Dodi Handy (973) 748-8082 (407) 585-1080 info@alfacell.com acel@efcg.net Press Release Source: Alfacell Corporation Wednesday October 19, 2005 8:30 am ET New ONCONASE® Non-Small Cell Lung Cancer Data Presented at ASTRO Annual Meeting BLOOMFIELD, N.J., October 19,
2005 – Alfacell Corporation (Nasdaq: ACEL) today announced that Intae
Lee, Ph.D., Department of Radiology, University of Pennsylvania, is
presenting new data on the effectiveness of ONCONASE® (ranpirnase)
against non-small cell lung cancer (NSCLC) at the 47th Annual Meeting
of the American Society of Therapeutic Radiology and Oncology (ASTRO),
held on October 16-20 in Denver. Dr. Lee's presentation is entitled,
'The Enhanced Efficacy Of Cisplatin And Carboplatin By The RNase
ONCONASE® On A549 Human Lung Cancer Xenografts Of Nude Mice.'
"In these studies, we observed several events, including whether apoptosis (programmed cell death) was induced by ONCONASE; whether ONCONASE could sensitize the efficacy of chemotherapeutic agents cisplatin and carboplatin, and the changes in tumor volume after treatments with ONCONASE in combination with either cisplatin or carboplatin," stated Dr. Lee. "The data from our research indicates that ONCONASE alone inhibited the tumor growth of A549 human NSCLC cells, and induced apoptosis of those cells. ONCONASE also enhanced the cytotoxic effects of cisplatin and carboplatin when both drugs were simultaneously administered and when cisplatin or carboplatin was added after ONCONASE, and increased the cisplatin-induced tumor growth delay. Finally, and importantly, for the treatment of large-size tumors previously treated unsuccessfully with various drugs, ONCONASE effectively showed the inhibition of tumor growth, while cisplatin and carboplatin did not show such tumoricidal effects." Dr. Lee concluded, "These results continue to illustrate the remarkable effect of ONCONASE against NSCLC." "Dr. Lee's elegant work builds on a significant number of studies that show ONCONASE enhances standard chemotherapeutic drugs -- even in the presence of drug resistance," stated Dr. Susanna Rybak, newest member of Alfacell's Scientific Advisory Board and former head of a laboratory at the National Cancer Institute (NCI) that helped develop the groundwork for RNase-based therapeutics. "One explanation may be found from Dr. Lee's previous observation that ONCONASE lowers tumor interstitial fluid pressure, one of the major causes of inadequate drug delivery into solid tumors." "These studies offer further validation of ONCONASE's potential as a novel and promising cytotoxic agent," stated Kuslima Shogen, Chief Executive Officer of Alfacell. "We will continue in our collaboration with Dr. Lee and the University of Pennsylvania to build a strong compendium of data that shows ONCONASE to have significant clinical utility in the treatment of NSCLC and other solid tumors." About Alfacell Corporation Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer, using its proprietary ribonuclease (RNase) technology platform. ONCONASE® (ranpirnase), Alfacell's lead investigational drug candidate, is currently being evaluated in several studies, including a Phase IIIb trial for malignant mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC). For more information, please visit www.alfacell.com. About Non-Small Cell Lung Cancer (NSCLC) According to the American Cancer Society, lung cancer is the leading cause of cancer deaths worldwide among men and women. NSCLC is the most common form of lung cancer, accounting for 80 percent of all lung cancer cases. In 2004, NSCLC accounted for approximately 160,000 deaths in the United States. According to industry analysts, the NSCLC drug market is projected to exceed $4 billion by 2012. This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Contact: Alfacell Corporation: Investor/Media Relations: Kuslima Shogen Elite Financial Communications Robert Love Dodi Handy (973) 748-8082 (407) 585-1080 info@alfacell.com acel@efcg.net Press Release Source: Alfacell Corporation Thursday October 20, 2005 8:45 am ET Alfacell Corporation to Present at C.E. Unterberg Towbin Emerging Growth Life Sciences Conference BLOOMFIELD, N.J., October 20,
2005 – Alfacell Corporation (Nasdaq: ACEL), a biopharmaceutical company
focused on the discovery, development and commercialization of novel
ribonuclease (RNase) therapeutics for cancer and other life-threatening
diseases, today announced that Andrew Aromando, Senior Vice President,
Commercial Development and Operations, is scheduled to present at the C.E. Unterberg Towbin Emerging Growth Life Sciences Conference at The Palace Hotel in New York at 9:20 AM EDT on Wednesday, October 26.
The presentation will be webcast live via the Alfacell company website at www.alfacell.com, and will be available for replay. Alfacell is one of approximately 90 invited Biotechnology, Medical Devices and Diagnostics, and Specialty Pharmaceuticals companies scheduled to present. For more information about the conference, visit www.unterberg.com. About Alfacell Corporation Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer, using its proprietary RNase technology platform. ONCONASE® (ranpirnase), Alfacell's lead investigational drug candidate, is currently being evaluated in several studies, including a Phase IIIb registration study for malignant mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC). For more information, please visit www.alfacell.com. This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Contact: Alfacell Corporation: Investor/Media Relations: Kuslima Shogen Elite Financial Communications Group Robert Love Dodi Handy (973) 748-8082 (407) 585-1080 info@alfacell.com acel@efcg.net Press Release Source: Alfacell Corporation Monday November 7, 2005 8:30 am ET Alfacell Corporation to Present at Rodman and Renshaw Techvest 7th Annual Healthcare Conference BLOOMFIELD, N.J., November 7,
2005 – Alfacell Corporation (Nasdaq: ACEL), a biopharmaceutical company
focused on the discovery, development and commercialization of novel
ribonuclease (RNase) therapeutics for cancer and other life-threatening
diseases, today announced that Andrew Aromando, Senior Vice President,
Commercial Development and Operations, is scheduled to present at the Rodman and Renshaw Techvest 7th Annual Healthcare Conference at the New York Palace Hotel on Monday, November 7 at 11:15 AM EST.
Alfacell is one of 290 invited public and private companies scheduled to present at the conference. In 2004, the conference attracted over 2,000 attendees. For more information about the conference, visit http://www.rodmanandrenshaw.com. About Alfacell Corporation Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer, using its proprietary RNase technology platform. ONCONASE® (ranpirnase), Alfacell's lead investigational drug candidate, is currently being evaluated in several studies, including a Phase IIIb registration study for malignant mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC). For more information, please visit http://www.alfacell.com. This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Contact: Alfacell Corporation: Investor/Media Relations: Kuslima Shogen Elite Financial Communications Robert Love Dodi Handy (973) 748-8082 (407) 585-1080 info@alfacell.com acel@efcg.net Press Release Source: Alfacell Corporation Monday November 28, 2005 9:56 am ET Alfacell Corporation Launches New Investor Relations Section of Company Website BLOOMFIELD, N.J., November 28,
2005 – Alfacell Corporation (Nasdaq: ACEL), a biopharmaceutical company
focused on the discovery, development and commercialization of novel
ribonuclease (RNase) therapeutics for cancer and other life-threatening
diseases, today announced that the Company has upgraded its current
website at www.alfacell.com.
While some graphical modifications were made to the entire website, efforts to enhance the existing site were focused on the Investor Relations section. Many new features and components have been added to allow visitors access to a broader range of historical and contemporary data, and provides a new suite of tools to research and request information. "We would like to invite all of our shareholders, industry observers following our clinical programs, and others interested in our Company to visit our upgraded website," said Kuslima Shogen, Chairman and CEO of Alfacell. About Alfacell Corporation Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer, using its proprietary RNase technology platform. ONCONASE® (ranpirnase), Alfacell's lead investigational drug candidate, is currently being evaluated in several studies, including a Phase IIIb registration study for malignant mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC). For more information, please visit www.alfacell.com. This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Contact: Alfacell Corporation: Investor/Media Relations: Kuslima Shogen Elite Financial Communications Robert Love Dodi Handy (973) 748-8082 (407) 585-1080 info@alfacell.com acel@efcg.net Press Release Source: Alfacell Corporation Tuesday December 6, 2005 11:45 am ET Alfacell Corporation Announces Annual Shareholders Meeting BLOOMFIELD, N.J., December 6,
2005 – Alfacell Corporation (Nasdaq: ACEL), a biopharmaceutical company
focused on the discovery, development and commercialization of novel
ribonuclease (RNase) therapeutics for cancer and other life-threatening
diseases, today announced that its Annual Shareholder Meeting will be
held on Thursday, January 19, 2006 at 2:00PM EST in Somerset, NJ at the
Somerset Marriott.
The agenda is expected to include the election of the Company's new Board of Directors; updates from the management team on the ONCONASE® (ranpirnase) confirmatory Phase IIIb trial and ongoing preclinical and clinical programs, a review of other business activities, and a look forward to key milestones in 2006. For more information, please visit the Company's website at www.alfacell.com to view a copy of the Annual Letter to Shareholders from Kuslima Shogen, Chairman and CEO of Alfacell. About Alfacell Corporation Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer, using its proprietary RNase technology platform. ONCONASE® (ranpirnase), Alfacell's lead investigational drug candidate, is currently being evaluated in several studies, including a Phase IIIb registration study for unresectable malignant mesothelioma (UMM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC). For more information, please visit www.alfacell.com. This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. Contact: Alfacell Corporation: Investor/Media Relations: Kuslima Shogen Elite Financial Communications Robert Love Dodi Handy (973) 748-8082 (407) 585-1080 info@alfacell.com acel@efcg.net Return to Onconase Update Home Page |